Literature DB >> 9648876

Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis.

S E Browne1, A C Bowling, M J Baik, M Gurney, R H Brown, M F Beal.   

Abstract

Autosomal dominant familial amyotrophic lateral sclerosis (FALS) is associated with mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1). Previous studies have implicated the involvement of metabolic dysfunction in ALS pathogenesis. To further investigate the biochemical features of FALS and sporadic ALS (SALS), we examined SOD activity and mitochondrial oxidative phosphorylation enzyme activities in motor cortex (Brodmann area 4), parietal cortex (Brodmann area 40), and cerebellum from control subjects, FALS patients with and without known SOD mutations, SALS patients, and disease controls (Pick's disease, progressive supranuclear palsy, diffuse Lewy body disease). Cytosolic SOD activity, predominantly Cu/Zn SOD, was decreased approximately 50% in all regions in FALS patients with SOD mutations but was not significantly altered in other patient groups. Marked increases in complex I and II-III activities were seen in FALS patients with SOD mutations but not in SALS patients. We also measured electron transport chain enzyme activities in a transgenic mouse model of FALS. Complex I activity was significantly increased in the forebrain of 60-day-old G93A transgenic mice overexpressing human mutant SOD1, relative to levels in transgenic wild-type animals, supporting the hypothesis that the motor neuron disorder associated with SOD1 mutations involves a defect in mitochondrial energy metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648876     DOI: 10.1046/j.1471-4159.1998.71010281.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  29 in total

Review 1.  Mitochondrial dysfunction in familial amyotrophic lateral sclerosis.

Authors:  Liesbeth Faes; Geert Callewaert
Journal:  J Bioenerg Biomembr       Date:  2011-12       Impact factor: 2.945

Review 2.  Programmed cell death in amyotrophic lateral sclerosis.

Authors:  Christelle Guégan; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 3.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 4.  Complex genetics of amyotrophic lateral sclerosis.

Authors:  Catherine B Kunst
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

Review 5.  Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Lee J Martin
Journal:  IDrugs       Date:  2010-08

Review 6.  Mitochondria in neurodegeneration.

Authors:  E Lezi; Russell H Swerdlow
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Mitochondrial dysfunction in blood cells from amyotrophic lateral sclerosis patients.

Authors:  Johannes K Ehinger; Saori Morota; Magnus J Hansson; Gesine Paul; Eskil Elmér
Journal:  J Neurol       Date:  2015-04-18       Impact factor: 4.849

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  The legs at odd angles (Loa) mutation in cytoplasmic dynein ameliorates mitochondrial function in SOD1G93A mouse model for motor neuron disease.

Authors:  Ali Morsi El-Kadi; Virginie Bros-Facer; Wenhan Deng; Amelia Philpott; Eleanor Stoddart; Gareth Banks; Graham S Jackson; Elizabeth M C Fisher; Michael R Duchen; Linda Greensmith; Anthony L Moore; Majid Hafezparast
Journal:  J Biol Chem       Date:  2010-04-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.